Pharmaco-economic study and cost of care for chronic diseases: Case of Haemophilia in Morocco

Article Sidebar

PDF HTML
Submitted: March 13, 2020
Published: Apr 2, 2020
DOI: 10.29328/journal.japch.1001013
Keywords:
Pharmaco-economic study, Cost-effectiveness analysis, Haemophilia, Prophylaxis
Crossref
Scopus
Google Scholar
Europe PMC

Main Article Content

Khairoun C
Center of Pediatric Hematology and Oncology in rabat, Children’s Hospital, Faculty of Medicine and Pharmacy, Mohammed V University of RABAT, Morocco
Khorassani M
Center of Pediatric Hematology and Oncology in rabat, Children’s Hospital, Faculty of Medicine and Pharmacy, Mohammed V University of RABAT, Morocco
Kili A
Center of Pediatric Hematology and Oncology in rabat, Children’s Hospital, Faculty of Medicine and Pharmacy, Mohammed V University of RABAT, Morocco
Hssissen L
Center of Pediatric Hematology and Oncology in rabat, Children’s Hospital, Faculty of Medicine and Pharmacy, Mohammed V University of RABAT, Morocco
Kababri M
Center of Pediatric Hematology and Oncology in rabat, Children’s Hospital, Faculty of Medicine and Pharmacy, Mohammed V University of RABAT, Morocco
Khattab M
Center of Pediatric Hematology and Oncology in rabat, Children’s Hospital, Faculty of Medicine and Pharmacy, Mohammed V University of RABAT, Morocco

Abstract

This paper is an attempt to enrich the literature about the role that can play some economic approaches, such as cost-effectiveness analysis, in order to help medical stuffs to decide about the treatment to adopt in case of a chronic disease such as Haemophilia. Data from morocco were gathered in order to explain the importance of such approaches.

Article Details

C, K., M, K., A, K., L, H., M, K., & M, K. (2020). Pharmaco-economic study and cost of care for chronic diseases: Case of Haemophilia in Morocco. Journal of Advanced Pediatrics and Child Health, 3(1), 024–026. https://doi.org/10.29328/journal.japch.1001013
Research Articles

Copyright (c) 2020 Khairoun C, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Ministry of Health. National Chronic Disease Plan 2007-2011 [Internet]. 2007.

World Health Organization. WHO: Chronic diseases.

Carrier S, Morin P, Gross O, De La Tribonnière X. L'engagement de la personne dans les soins de santé et services sociaux: Regards croisés France-Québec: Presses de l'Université du Québec. 2017.

https://www.mloz.be/sites/default/files/publications/envol_cout_maladies_chroniques_0318.pdf

Hemophilia B in Morocco. Current state and outlook.

Emmanuil Kombarelis, willim P. J Clini Epidemiology. 2011; 47.

Hay CR, Brown S, Collins PW. le diagnosticet la gestion du facteur VII et IX,Centre d'hémophilie Br, Haematol. 2006; 133: 591-605.

Jenny Goudemand, Yves Laurien. 'hémophilie Orphanet Mai. 2006.

Kessler CM, Goldman L. Hemmoragic disorders :coagulation factor diferences,cecil Medecine 23rd ed,Philadelphia, Sauders Elsevier. 2007; 180.

Kessler CM, Mariani. manifestations cliniques et traitement de l'hémophilie,Hemostasis et Thrombosis 5èd Philadelphia. 2006; 887.

Khachidz M, Buil A, Viel KR, Porter S. Genetic determinants of normal variation in coagulation factor IX. Hemostasis Thrombosis. 2006; 4: 1537-1545.

Siegmund B, Richter H, Pollmann H. Need for prophylactic treatment in adult haemophilia A patients. Transfusion Medicine and Hemotherapy. 2009; 36: 283-288.

Suzuki Katsuhiko. Chronic inflammation as an immunological abnormality and effectiveness of exercise. Biomolecules. 2019; 9: 223. PubMed: https://pubmed.ncbi.nlm.nih.gov/31181700/

Cortesi, Paolo Angelo, Gianluca Trifirò, Simona Serao Creazzola, Giovanni Improta, et al. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors. Thromb Haemost. 120.02 (2020): 216-228. PubMed: https://pubmed.ncbi.nlm.nih.gov/31887777/

Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol. 1996; 92: 973-978. PubMed: https://pubmed.ncbi.nlm.nih.gov/8616096/

Matsumura Risa. Pharmacokinetics of Extended Half-Life Factor VIII Products By my PKFiTR Is Useful for Personalized Treatment in Children with Severe Hemophilia a. 2019; 1127.